BIO89-100 Market Size, Forecast, and Emerging Insight - 2032

"BIO89-100 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about BIO89-100 for Non-alcoholic Steatohepatitis (NASH) in the seven major markets. A detailed picture of the BIO89-100 for NASH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the BIO89-100 for NASH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BIO89-100 market forecast analysis for NASH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary:

BIO89-100 is a compound that specifically targets and activates a receptor known as fibroblast growth factor 21 (FGF21). FGF21 is a hormone involved in regulating glucose and lipid metabolism, and it has been shown to have potential therapeutic effects in NASH.

Preclinical studies and early-stage clinical trials of BIO89-100 have shown promising results in improving metabolic parameters and reducing liver fat accumulation in patients with NASH. The drug is designed to address the underlying causes of NASH, such as insulin resistance and inflammation, and potentially slow down or reverse the progression of the disease. In March 2023, 89bio, Inc. announced positive topline data from the Phase IIb ENLIVEN trial evaluating treatment with pegozafermin in patients with NASH.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the BIO89-100 description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on BIO89-100 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the BIO89-100 research and development activities in NASH across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around BIO89-100.
• The report contains forecasted sales of BIO89-100 for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for BIO89-100 in NASH.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BIO89-100 Analytical Perspective by DelveInsight

• In-depth BIO89-100 Market Assessment

This report provides a detailed market assessment of BIO89-100 for Non-alcoholic Steatohepatitis (NASH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• BIO89-100 Clinical Assessment

The report provides the clinical trials information of BIO89-100 for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BIO89-100 dominance.
• Other emerging products for NASH are expected to give tough market competition to BIO89-100 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of BIO89-100 in NASH.
• Our in-depth analysis of the forecasted sales data of BIO89-100 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BIO89-100 in NASH.

Key Questions:

• What is the product type, route of administration and mechanism of action of BIO89-100?
• What is the clinical trial status of the study related to BIO89-100 in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BIO89-100 development?
• What are the key designations that have been granted to BIO89-100 for NASH?
• What is the forecasted market scenario of BIO89-100 for NASH?
• What are the forecasted sales of BIO89-100 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to BIO89-100 for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?